Mandana Kamgar, MD

Open enrollment across a mixed-phase pipeline

According to ClinicalTrials.gov-derived indexes, Mandana Kamgar, MD sits in the upper half of US sponsors by registered trial count (#7,388 of 15,742 sponsors by registered trial count).

1 total trials 1 currently recruiting upper half by trial count

Mandana Kamgar, MD: 1 sponsored US clinical trial, 1 recruiting.

Mandana Kamgar, MD sponsors 1 registered US clinical trials on ClinicalTrials.gov, 1 of them currently recruiting. The most-studied condition in this pipeline is Pancreatic Ductal Adenocarcinoma, with 1 trials.

Mid-pack sponsor footprint

Mandana Kamgar, MD is in the upper half of sponsors by trial count (#7,388 of 15,742 sponsors by registered trial count). Use the pipeline list and therapeutic areas to see what drives that mid-pack volume.

Open and recent trials

1 total, page 1 of 1

RECRUITING

A Registry to Capture Patient Outcomes With KRAS G12R Altered Advanced Pancreatic Ductal Adenocarcinoma Treated With MEK Inhibitor-based Combination Therapy

NCT05630989

Therapeutic Areas

Pancreatic Ductal Adenocarcinoma 1

What is open in the Mandana Kamgar, MD pipeline

1 recruiting of 1 indexed (100% open).

Phase labels are sparse on this sponsor index, so phase mix is not charted here.

Top condition: Pancreatic Ductal Adenocarcinoma (1 trial), 0 others listed.

How open-pipeline share is computed

Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.

Mandana Kamgar, MD: open-pipeline peers nationwide

Peers matched on 1 registered trials and 100% open enrollment, not the therapeutic-area sidebar.

Mandana Kamgar, MD sits below the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot). 2×2 strategic matrix plotting 9 entities by Total trials (X) and Recruiting share (Y), with a crosshair dividing the plot into four quadrants. Higher volume & more openFocused & more openHigher volume, mostly closedSmaller & mostly closed 012345 0%50%100%150% Total trials Recruiting share Mandana Kamgar, MD1200 Pharma1ST Biotherapeutics3 Waves Wellness3EO HealthAAVantgarde Bio SrlAcorn BiolabsAcrivon TherapeuticsADARx Pharmaceuticals
Mandana Kamgar, MD sits below the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot).

Mandana Kamgar, MD sits below the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.

Sponsors near 1 trials (± recruiting share)

Sponsors near 100% open enrollment (± trial volume)

Related

Read our methodology - how this data is sourced, computed, and verified.

What to do with this Mandana Kamgar, MD page

1 registered trials is a research-attention snapshot, not an endorsement of Mandana Kamgar, MD or any single study.

  • 1 of Mandana Kamgar, MD's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
  • Pancreatic Ductal Adenocarcinoma is the condition Mandana Kamgar, MD studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Pancreatic Ductal Adenocarcinoma trials
  • Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Mandana Kamgar, MD pipeline card: 1 registered trials from official public datasets.Report a data error.